Results 91 to 100 of about 21,108 (240)

Implementation of guideline‐recommended medical therapy for patients with heart failure in Europe

ESC Heart Failure, Volume 12, Issue 2, Page 790-798, April 2025.
Abstract Physicians' adherence to guideline‐recommended heart failure (HF) treatment remains suboptimal, especially regarding the target doses. In particular, there is evidence that non‐cardiologists are less compliant with HF guideline recommendations. This is likely to have a detrimental impact on patients' survival, readmissions and quality of life.
Maurizio Volterrani, Petar Seferovic, Gianluigi Savarese, Ilaria Spoletini, Egidio Imbalzano, Antoni Bayes‐Genis, Ewa Jankowska, Michele Senni, Marco Metra, Ovidiu Chioncel, Andrew J. S. Coats, Giuseppe M. C. Rosano   +11 more
wiley   +1 more source

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul, Robert J. Mentz, Rebecca Young, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Piotr Ponikowski, Adriaan Voors, Stefano Corda, Ciaran McMullan, Christopher M. O'Connor, Kevin J. Anstrom, Paul W. Armstrong, for the VICTORIA Study Group   +13 more
wiley   +1 more source

Quality measure attainment with dapagliflozin plus metformin extended-release as initial combination therapy in patients with type 2 diabetes: a post hoc pooled analysis of two clinical studies

, 2016
Kelly F Bell, Arie Katz, John J Sheehan AstraZeneca, Wilmington, DE, USA Background: The use of quality measures attempts to improve safety and health outcomes and to reduce costs. In two Phase III trials in treatment-naive patients with type 2
Bell KF, Katz A, Sheehan JJ
core  

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

ESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao, Yang Chen, Zhiyu Ling, Helmut Pürerfellner, Martin Martinek, Michael Derndorfer, Johannes Niel, Ramin Ebrahimi, Matthias Heukäufer, Sarah Janschel, Davide Di Vece, Klaus Empen, Astrid Hummel, Bishwas Chamling, Piotr Futyma, Fahim Ebrahimi, Márcio G. Kiuchi, Shaowen Liu, Yuehui Yin, Alexandra Schratter, Willem‐Jan Acou, Philipp Sommer, Boris Schmidt, Julian K. R. Chun, Christian Meyer, Marcus Dörr, Christian Templin, Shaojie Chen   +27 more
wiley   +1 more source

Pilot study on the effects of dapagliflozin on echocardiographic parameters in dogs with symptomatic myxomatous mitral valve disease

Veterinary and Animal Science
Myxomatous mitral valve disease (MMVD) is the most common valvular heart disease in geriatric small-to medium-sized dogs. Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT-2i), has shown promise in managing heart failure in human patients ...
Nakkawee Saengklub, Anusak Kijtawornrat, Robert L. Hamlin   +2 more
doaj   +1 more source

Dapagliflozin for the treatment of type 2 diabetes: a review of the literature

, 2014
Mujahid A Saeed,1 Parth Narendran2 1Department of Diabetes, University Hospital Birmingham NHS Foundation Trust, 2School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, UK Objective: Dapagliflozin was the first drug in a ...
Saeed MA, Narendran P
core  

Prognostic role of TAPSE to PASP ratio in outpatients with left ventricular systolic dysfunction

ESC Heart Failure, Volume 12, Issue 2, Page 912-922, April 2025.
Abstract Aims Few data are available regarding the role of tricuspid annulus plane systolic excursion to pulmonary artery systolic pressure (TAPSE/PASP), a measurement of right ventricular to pulmonary artery coupling, in patients with chronic heart failure and left ventricular systolic dysfunction.
Mauro Riccardi, Matteo Pagnesi, Rossana Corso, Antonio M. Sammartino, Daniela Tomasoni, Riccardo M. Inciardi, Carlo M. Lombardi, Marianna Adamo, Savina Nodari, Marco Metra   +9 more
wiley   +1 more source

Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis

ESC Heart Failure, Volume 12, Issue 2, Page 1358-1373, April 2025.
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen, Jiahao Shi, Yue Wu, Lizhu Miao, Zilin Wang, Yixuan Wang, Siwei Xu, Yu Lou   +7 more
wiley   +1 more source

Dapagliflozin acutely suppressed BAT thermogenesis by reducing sympathetic nerve activity.

, 2016
Oxygen consumption during the 18 hours following dapagliflozin administration (A). Respiratory exchange rate (RER) during the 18 hours following dapagliflozin administration (B). Relative amounts of UCP1 (C) and PGC1α (D) mRNA in BAT. BAT (E) and rectal (
Shinjiro Kodama (548195), Junta Imai (548196), Tetsuya Yamada (219211), Yuta Shirai (2560159), Kei Takahashi (57099), Kazuhiro Nakamura (652922), Yoichiro Asai (2560165), Yuichiro Munakata (2560153), Kenji Uno (548200), Yumiko Chiba (2560156), Takashi Sugisawa (2560162), Shojiro Sawada (548197), Hideki Katagiri (219214), Sohei Tsukita (548198)   +13 more
core   +1 more source

Dapagliflozin treatment improves T1DM-induced metabolic changes.

, 2022
Dapagliflozin treatment improves T1DM-induced metabolic changes.
Attila Fintha (12101742), Laszlo J. Wagner (12101748), Adrienn Barczi (12101745), Adar Saeed (12101739), Dora B. Balogh (12101754), Attila J. Szabo (12101751), Judit Hodrea (12101736), Agnes Molnar (2158924), Andrea Fekete (318162)   +8 more
core   +1 more source